Olanzapine
- TRADE NAMES: Symbyax (Lilly); Zyprexa (Lilly); Zyprexa Relprevv (Lilly)
- INDICATIONS: Schizophrenia, bipolar I disorder
- CLASS: Antipsychotic, Muscarinic antagonist
- HALF-LIFE: 21–54 hours
Alcohol, Antihypertensive agents, Carbamazepine, Ciprofloxacin, CNS acting drugs, Diazepam, Dopamine agonists, Eszopiclone, Fluoxetine, Fluvoxamine, Insulin Degludec, Insulin Detemir, Insulin Glargine, Levodopa, Lithium, Metoclopramide, Tetrabenazine, Valproic Acid
PREGNANCY CATEGORY: C
Can cause DRESS and other serious skin reactions.
Symbyax is olanzapine and fluoxetine; Zypraxa Relprevv is olanzapine pamoate.
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Zyprexa Relprevv: POST-INJECTION DELIRIUM/SEDATION SYNDROME
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of olanzapine in the Taylor & Francis journal Expert Opinion on Drug Safety. See also a separate review of olanzapine in combination with fluoxetine in the drug profile for fluoxetine. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/13/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric